AMPK Activators in Research: AICAR, MOTS-c, and Metabolic Mimetics

The idea of an “exercise pill” has captured public imagination, but the underlying science is far more nuanced — and more interesting — than that label suggests. At the center of this research sits AMPK, a master metabolic sensor that coordinates the cellular response to energy stress. This guide examines three compounds that activate AMPK through distinct mechanisms: AICAR (a direct pharmacological activator), MOTS-c (a mitochondrial-derived peptide), and SLU-PP-332 (a synthetic nuclear receptor agonist). Understanding how they differ is essential for researchers designing metabolic studies.

AMPK: The Master Energy Sensor

Before examining the individual compounds, it is necessary to understand the pathway they target. AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine kinase expressed in virtually all eukaryotic cells. It functions as the cell’s primary energy sensor, continuously monitoring the ratio of AMP and ADP to ATP — the fundamental currencies of cellular energy.

Structure and Activation

AMPK consists of three subunits: a catalytic alpha subunit (with two isoforms, alpha-1 and alpha-2), a scaffolding beta subunit (beta-1 and beta-2), and a regulatory gamma subunit (gamma-1, gamma-2, and gamma-3). The gamma subunit contains four cystathionine-beta-synthase (CBS) domains that form nucleotide-binding sites. When cellular energy is depleted — during exercise, fasting, or hypoxia — AMP and ADP levels rise relative to ATP, and these nucleotides bind to specific sites on the gamma subunit.

This binding triggers a conformational change that activates AMPK through three complementary mechanisms:

1. Allosteric activation: AMP binding directly increases AMPK catalytic activity approximately 2–5 fold.
2. Promoting phosphorylation: AMP binding makes AMPK a better substrate for its upstream kinase LKB1 (liver kinase B1), which phosphorylates the critical threonine-172 (Thr172) residue on the alpha subunit.
3. Inhibiting dephosphorylation: AMP and ADP binding protect the phosphorylated Thr172 from protein phosphatases, maintaining AMPK in its active state.

A second upstream kinase, CaMKKbeta (calcium/calmodulin-dependent kinase kinase beta), can also phosphorylate Thr172 in response to elevated intracellular calcium — providing an alternative, nucleotide-independent activation route that is important in certain tissues and conditions.

Downstream Effects: The Metabolic Switch

Once activated, AMPK acts as a metabolic switch, simultaneously activating catabolic pathways that generate ATP and inhibiting anabolic pathways that consume ATP. The downstream effects include:

• Glucose uptake: AMPK promotes GLUT4 transporter translocation to the cell surface, increasing glucose uptake independently of insulin signaling.
• Fatty acid oxidation: AMPK phosphorylates and inhibits acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and relieving inhibition of carnitine palmitoyltransferase 1 (CPT1), thereby increasing mitochondrial fatty acid import and oxidation.
• Mitochondrial biogenesis: Through PGC-1alpha activation, AMPK promotes the transcription of nuclear-encoded mitochondrial genes, increasing mitochondrial density over time.
• Autophagy: AMPK activates ULK1, initiating the autophagy cascade that clears damaged organelles and misfolded proteins.
• Protein and lipid synthesis inhibition: AMPK inhibits mTORC1, the master anabolic regulator, suppressing energy-intensive biosynthetic pathways.

In skeletal muscle, these effects collectively mimic many of the metabolic adaptations produced by endurance exercise — which is precisely why AMPK activators have been called “exercise mimetics.”

AICAR: The Classical AMPK Activator

5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR, also called acadesine) is the most widely used pharmacological AMPK activator in research. First synthesized as a potential cardiac protective agent, it became the foundational tool for studying AMPK biology and was the compound that first demonstrated the “exercise mimetic” concept in vivo.

The ZMP Mechanism

AICAR itself does not directly activate AMPK. It is an adenosine analog that enters cells via adenosine transporters and is phosphorylated by adenosine kinase to form ZMP (5-aminoimidazole-4-carboxamide ribonucleotide, also called AICA ribotide). ZMP is structurally analogous to AMP and binds to the same sites on the AMPK gamma subunit, mimicking cellular energy depletion without actually depleting ATP.

This is an important distinction. Exercise activates AMPK by genuinely increasing the AMP:ATP ratio through ATP consumption. AICAR/ZMP activates AMPK by mimicking high AMP levels while cellular energy charge remains normal. The downstream signaling may overlap substantially, but the cellular context differs.

Although ZMP is a less potent AMPK activator than AMP in cell-free assays, it accumulates to millimolar concentrations within cells, which more than compensates for its lower per-molecule potency. Interestingly, exercise itself induces endogenous ZMP production in a time-dependent manner, suggesting that the ZMP/AMPK axis is a natural component of the exercise signaling response.

Exercise Mimetic Effects

The landmark 2008 study by Narkar, Downes, and colleagues at the Salk Institute demonstrated that chronic AICAR treatment in sedentary mice increased running endurance by approximately 44% — without any exercise training. The AICAR-treated mice showed conversion of fast-twitch (type II) muscle fibers toward the fatigue-resistant type I (slow-twitch) phenotype, increased expression of oxidative metabolism genes, and enhanced mitochondrial content.

These findings generated enormous public interest (and the unfortunate “exercise pill” label), but the research implications were more specific: AMPK activation is sufficient to drive at least some of the endurance adaptations normally produced by exercise training. Subsequent studies have shown that AICAR-induced improvements include enhanced insulin sensitivity, improved glucose metabolism, and altered lipid metabolism — all effects consistent with exercise adaptation.

More recent research has examined AICAR’s effects on aging muscle. A 2025 study published in Aging Cell demonstrated that chronic AICAR treatment in old mice reversed age-related changes in exercise performance and skeletal muscle gene expression, suggesting that AMPK activation may address some aspects of age-related muscle decline.

AMPK-Independent Effects

A critical consideration for researchers: AICAR has significant AMPK-independent effects that can confound experimental interpretation. A comprehensive 2021 systematic review identified multiple AICAR actions that do not require AMPK, including effects on adenosine signaling (since AICAR is an adenosine analog), purine metabolism, and direct ZMP interactions with other AMP-responsive enzymes. Researchers using AICAR as an “AMPK activator” must account for these off-target effects, ideally by including AMPK-knockout controls or using additional, structurally distinct AMPK activators for confirmation.

MOTS-c: The Mitochondrial Exercise Mimetic

MOTS-c (Mitochondrial Open reading frame of the 12S rRNA type-c) represents a fundamentally different approach to AMPK activation. Discovered in 2015 by Changhan Lee’s group at the University of Southern California, MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome — making it one of only a handful of known mitochondrial-derived peptides (MDPs) with signaling functions.

A Signal from the Mitochondria

The discovery that mitochondria produce bioactive signaling peptides was itself revolutionary. Mitochondria were long viewed as simple energy-producing organelles, but the identification of MOTS-c (and the related peptide humanin) revealed that the mitochondrial genome encodes information beyond the 13 structural proteins and 24 RNA molecules that were traditionally recognized.

MOTS-c is produced from a short open reading frame within the 12S rRNA gene of mitochondrial DNA. It is detectable in plasma and various tissues, and its levels decline with age — paralleling the age-related decline in mitochondrial function that is a hallmark of biological aging.

Mechanism of AMPK Activation

Unlike AICAR, which mimics AMP directly, MOTS-c activates AMPK through an indirect mechanism. Its primary cellular action is inhibition of the folate cycle and its connected de novo purine biosynthesis pathway. By blocking purine synthesis, MOTS-c causes accumulation of the folate cycle intermediate AICAR (yes, the same molecule) and its phosphorylated form ZMP. In other words, MOTS-c activates AMPK by endogenously generating the same ZMP that exogenous AICAR produces — but through an upstream metabolic intervention rather than direct supplementation.

This difference in mechanism has practical implications. MOTS-c’s AMPK activation is coupled to broader metabolic reprogramming (folate cycle disruption, altered one-carbon metabolism) that may contribute additional effects beyond what AICAR alone produces.

Nuclear Translocation

Perhaps the most remarkable aspect of MOTS-c biology is its ability to translocate from the cytoplasm to the nucleus during metabolic stress. A 2018 study demonstrated that MOTS-c moves to the nucleus in an AMPK-dependent manner and directly regulates nuclear gene expression — particularly genes involved in the antioxidant response element (ARE) pathway. This mitochondria-to-nucleus signaling represents a novel form of retrograde communication that challenges traditional models of mitochondrial function.

Exercise and Aging Research

MOTS-c has emerged as a particularly compelling subject in exercise and aging research:

• Exercise-induced expression: In humans, exercise induces approximately 11.9-fold increases in endogenous MOTS-c levels in skeletal muscle, with circulating levels increasing 1.6-fold during exercise and returning to baseline within 4 hours. This suggests that MOTS-c is an endogenous exercise signal, not just a pharmacological tool.
• Age-related decline: MOTS-c levels in skeletal muscle and blood decrease with age in mice, correlating with age-related metabolic decline and reduced exercise capacity.
• Physical performance enhancement: Exogenous MOTS-c administration significantly enhances physical performance in young, middle-aged, and old mice. Late-life intermittent MOTS-c treatment (initiated at 23.5 months — roughly equivalent to 70+ human years) increased physical capacity and healthspan markers.
• Insulin sensitivity: MOTS-c improves skeletal muscle glucose metabolism and reverses age-related insulin resistance in mice, suggesting relevance to metabolic disease research.
• Acute exercise augmentation: A single dose of MOTS-c supplementation augments acute exercise performance by approximately 12–15% in animal models.

For a detailed examination of MOTS-c mechanisms and research applications, see our MOTS-c Research Guide.

SLU-PP-332: The Nuclear Receptor Approach

SLU-PP-332 represents a third, mechanistically distinct approach to exercise mimicry. Rather than directly activating AMPK or its upstream pathways, SLU-PP-332 is a synthetic agonist of the estrogen-related receptors (ERRs) — nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and muscle fiber type specification.

ERR Biology

The estrogen-related receptors (ERR-alpha, ERR-beta, and ERR-gamma) are orphan nuclear receptors with no known natural endogenous ligand (hence “orphan”). Despite their name, they do not bind estrogen. They are transcription factors that directly regulate genes involved in mitochondrial function, fatty acid oxidation, and energy homeostasis — many of the same pathways activated by exercise and AMPK signaling.

ERR-gamma, in particular, is highly expressed in oxidative tissues (heart, kidney, slow-twitch muscle) and is a key regulator of the type I (slow-twitch, fatigue-resistant) muscle fiber program. This made ERRs an attractive pharmacological target for exercise mimicry.

Mechanism and Effects

SLU-PP-332 is a pan-ERR agonist, activating all three ERR isoforms. A 2024 study published in the Journal of Medicinal Chemistry demonstrated that SLU-PP-332 activates an acute aerobic exercise transcriptional program in an ERR-alpha-dependent manner. Its effects include:

• Increased mitochondrial function and cellular respiration in skeletal muscle cells
• Conversion of muscle fibers toward the type IIa oxidative phenotype
• Enhanced exercise endurance in mice
• Increased whole-body energy expenditure and fatty acid oxidation
• Decreased fat mass accumulation in mouse models of obesity

Notably, SLU-PP-332’s mechanism is fundamentally different from AICAR or MOTS-c. Rather than mimicking energy depletion (as AICAR does) or producing an endogenous stress signal (as MOTS-c does), SLU-PP-332 directly activates the transcriptional program that exercise normally induces through ERR-mediated gene regulation. It works at the level of gene transcription rather than metabolic signaling.

For detailed research on SLU-PP-332, see our SLU-PP-332 Research Guide.

Head-to-Head Comparison

Understanding the differences among these three compounds is critical for researchers selecting the appropriate tool for their experimental questions.

Feature	AICAR	MOTS-c	SLU-PP-332
Chemical class	Nucleoside analog	Mitochondrial-derived peptide (16 aa)	Synthetic small molecule (ERR agonist)
Primary target	AMPK (via ZMP → gamma subunit)	Folate cycle → endogenous ZMP → AMPK	ERR-alpha/beta/gamma (nuclear receptors)
AMPK activation	Direct (ZMP mimics AMP)	Indirect (via purine synthesis inhibition)	Downstream/parallel (not direct AMPK activation)
Endogenous?	ZMP is produced during exercise	Yes — mitochondrial-encoded, exercise-induced	No — fully synthetic
Age-related decline	Not established	Yes — declines with age in muscle and plasma	N/A (synthetic)
Muscle fiber effects	Type II → type I conversion	Metabolic enhancement across fiber types	Type II → type IIa (oxidative) conversion
Endurance improvement	~44% in sedentary mice	Significant in young, middle-aged, and old mice	Enhanced endurance in mice
Metabolic effects	Glucose uptake, FA oxidation, insulin sensitivity	Glucose metabolism, insulin sensitivity, folate cycle	Energy expenditure, FA oxidation, fat mass reduction
Nuclear translocation	No	Yes — AMPK-dependent nuclear import	N/A (ERRs are nuclear receptors)
Off-target concerns	Adenosine signaling, purine metabolism	Folate cycle disruption, one-carbon metabolism	ERR effects in non-muscle tissues
Research maturity	High — decades of published data	Moderate — discovered 2015, rapidly growing	Early — first publications 2023-2024

The Exercise Mimetic Concept: Promise and Limitations

The term “exercise mimetic” deserves scrutiny. Exercise produces an extraordinarily complex set of physiological responses — mechanical loading of bones and joints, cardiovascular conditioning, neural adaptation, endocrine signaling, immune modulation, and psychological effects — in addition to the metabolic adaptations that AMPK activators target. No pharmacological agent reproduces this full spectrum of effects.

What AICAR, MOTS-c, and SLU-PP-332 actually mimic is a specific subset of exercise adaptations: the metabolic reprogramming of skeletal muscle toward an oxidative, endurance-adapted phenotype. This is valuable for research purposes — it allows investigators to dissect the metabolic component of exercise adaptation from its mechanical, cardiovascular, and neural components. But it should not be confused with replicating exercise itself.

The concept is most useful in aging research, where age-related declines in AMPK responsiveness, mitochondrial function, and muscle metabolic capacity may contribute to frailty and metabolic disease. In this context, pharmacological AMPK activation or ERR agonism could theoretically restore some of the metabolic benefits that exercise provides — particularly in populations where exercise capacity is limited by disability, disease, or extreme age.

Practical Research Considerations

Choosing the Right Tool

Each compound has specific advantages depending on the research question:

• AICAR is the best-characterized AMPK activator and the default choice for studies requiring well-established pharmacology and extensive published reference data. However, its AMPK-independent effects must be controlled for.
• MOTS-c is ideal for studies examining endogenous exercise signaling, aging, mitochondria-to-nucleus communication, or the physiological role of mitochondrial-derived peptides. Its endogenous nature and age-related decline make it particularly relevant to translational aging research.
• SLU-PP-332 is the most appropriate choice for studies focused specifically on transcriptional regulation of the exercise program, ERR biology, or metabolic reprogramming at the gene expression level. Its early-stage status means less reference data but also more novelty.

For detailed individual compound guides, see our AICAR Research Guide, MOTS-c Research Guide, and SLU-PP-332 Research Guide. Researchers interested in the broader context of mitochondrial peptide signaling may also find our mitochondrial peptides overview informative.

Summary of Key Research References

Study	Year	Type	Focus	Reference
Garcia & Shaw	2017	Review	AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance	PMC5553560
Hardie et al.	2016	Review	AMPK: an energy-sensing pathway with multiple inputs and outputs	PMC5881568
Asby et al.	2015	Review	AMPK activators: mechanisms of action and physiological activities	PMC4855276
Marcinko & Steinberg	2021	Systematic Review	AICAr as a widely used AMPK activator with important AMPK-independent effects	PMC8147799
Hardee et al.	2025	Research Article	Chronic AICAR treatment reverses age-related changes in exercise performance	PMC11886611
Lee et al.	2015	Research Article	MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance	PMC4350682
Kim et al.	2018	Research Article	MOTS-c translocates to the nucleus to regulate nuclear gene expression during metabolic stress	PMC6185997
Reynolds et al.	2021	Research Article	MOTS-c is an exercise-induced regulator of age-dependent physical decline	PMC7817689
D’Urso et al.	2023	Review	MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation	PMC9905433
Billon et al.	2024	Research Article	Synthetic ERR agonist (SLU-PP-332) alleviates metabolic syndrome	PMC10801787

Written by NorthPeptide Research Team

---

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research. It does not constitute medical advice, treatment recommendations, or an endorsement for any therapeutic purpose. The research discussed herein is predominantly preclinical, and results may not translate to human outcomes. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving these compounds.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes.